Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;81(5):653-660.
doi: 10.1111/his.14766. Epub 2022 Aug 23.

The histological spectrum of ARB-induced gastritis

Tanner Storozuk  1 , Ian Brown  2 , Stephen Lagana  3 , Maria Westerhoff  4 , Namrata Setia  1 , John Hart  1 , Lindsay Alpert  1
Affiliations

The histological spectrum of ARB-induced gastritis

Tanner Storozuk et al. Histopathology. 2022 Nov.

Abstract

Aims: Olmesartan, an angiotensin receptor blocker (ARB) used for hypertension management, is known to cause a sprue-like enteropathy in a subset of patients. Rare cases of gastritis occurring with ARB use have also been reported, but the histological features of ARB-induced gastritis and the response to drug cessation have not been examined in a dedicated case-series.

Methods and results: Cases of suspected ARB-induced gastritis were identified from the pathology archives of four institutions. Haematoxylin and eosin (H&E) slides from gastric biopsies were reviewed. Fifteen patients (14 female, one male) were identified. The most common presenting symptoms were diarrhoea (10) and weight loss (six). Gastric biopsies commonly showed a full-thickness active chronic gastritis with surface epithelial injury involving the antrum and body. Glandular atrophy, intra-epithelial lymphocytosis and/or subepithelial collagen thickening were also present in some cases. Duodenal involvement, including villous atrophy, intra-epithelial lymphocytosis and/or collagenous sprue, was identified in 11 of 13 cases with concurrent duodenal biopsies. Following drug cessation, symptomatic improvement occurred in all 11 cases for which follow-up data were available. Histological resolution occurred in five of eight cases with follow-up gastric biopsies, with improvement seen in the remaining three biopsies.

Conclusion: ARB-induced gastritis typically presents as active chronic gastritis, frequently with associated surface epithelial injury. Glandular atrophy, intra-epithelial lymphocytosis and/or subepithelial collagen thickening may also be present. These gastric changes can be seen without associated duodenal injury in rare cases, and they should alert the pathologist to the possibility of ARB-induced injury. Drug cessation results in marked symptomatic and histological improvement.

Keywords: ARB; enteropathy; gastritis; olmesartan.

PubMed Disclaimer

Conflict of interest statement

S. L. was previously involved in litigation involving olmesartan, and is currently involved in litigation involving valsartan. The other authors of this study have indicated that they have no conflicts of interest that relate to the content of this study.

Figures

Figure 1
Figure 1
Four cases showing active chronic gastritis in the setting of angiotensin receptor blocker ARB. therapy. The surface epithelium is also attenuated and mucin‐depleted, with foci of epithelial detachment from the underlying basement membrane.
Figure 2
Figure 2
A, Biopsy of the gastric body showing active chronic gastritis accompanied by glandular atrophy. B, A gastrin immunostain revealed no gastrin cells, supporting the diagnosis of atrophy involving gastric body mucosa. C, Follow‐up biopsies revealed histological resolution.
Figure 3
Figure 3
Antral biopsy showing subepithelial collagen thickening and detachment of the overlying surface epithelium.
Figure 4
Figure 4
Antral biopsy showing a lymphoplasmacytic lamina propria infiltrate and intra‐epithelial lymphocytosis, diagnostic of lymphocytic gastritis.
See this image and copyright information in PMC

References

    1. Kamal A, Fain C, Park A et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue‐like enteropathy: a systematic review. Gastroenterol. Rep. 2019;7;162–167. - PMC - PubMed
    1. Rubio‐Tapia A, Herman ML, Ludvigsson JF et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin. Proc. 2012;87;732–738. - PMC - PubMed
    1. Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue‐like enteropathy associated with olmesartan. Aliment. Pharmacol. Ther. 2014; 40; 16–23. - PubMed
    1. Taylor R, Chapman C. Olmesartan‐induced collagenous gastritis, duodenitis, and colitis. Am. J. Gastroenterol. 2014; 109; S257.
    1. Shenbagaraj L, Swift G. Olmesartan‐associated severe gastritis and enteropathy. BMJ Case Rep. 2018; 11; e226133. - PMC - PubMed

Substances